When was Alentis Therapeutics founded?

Alentis Therapeutics was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Alentis Therapeutics located?

Alentis Therapeutics is headquartered in Basel, Switzerland.

How many employees does Alentis Therapeutics have?

As of Jun 30, 2026, the latest employee count at Alentis Therapeutics is 72.

Is Alentis Therapeutics a funded company?

Alentis Therapeutics is a funded company, having raised a total of $366M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 29, 2019.

How much is Alentis Therapeutics worth?

The latest valuation of Alentis Therapeutics is $***** as of Jun 15, 2021.

When was the latest funding round of Alentis Therapeutics?

Alentis Therapeutics' latest funding was a $***** Series D round on Nov 12, 2024, with participation from 8 investors. Its primary sector is Oncology. In Switzerland, the Oncology sector has seen $76.2M in funding in 2026 to date.

Where does Alentis Therapeutics rank among its competitors?

Alentis Therapeutics ranks 20th amongst 249 active competitors, of which 75 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Alentis Therapeutics, which secured $181M in Nov, 2024.

Who are the top competitors of Alentis Therapeutics?

Alentis Therapeutics' top competitors include argenx, Alexion and Halozyme. Among them, Alentis Therapeutics secured the most recent funding round in November, 2024.

Alentis Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Alentis Therapeutics is a series D company based in Basel (Switzerland), founded in 2019 by Thomas Baumert. It operates as a Developer of therapies for treating fibrosis, cirrhosis, and liver cancer. Alentis Therapeutics has raised $366M in funding from investors like Novo Holdings, Jeito and Orbimed, with a current valuation of $*****. The company has 249 active competitors, including 75 funded and 72 that have exited. Its top competitors include companies like argenx, Alexion and Halozyme.

Company Details

Developer of therapies for treating fibrosis, cirrhosis, and liver cancer. They have developed a gene expression platform. Their drug candidates (monoclonal antibodies) target a cell surface protein, which is being investigated for liver disease and cancer. The products include ALE-F02, CLDN1 for Liver Fibrosis (F3/F4) and kidney fibrosis, and ALE-C04, CLDN1 for Hepatocellular Carcinoma (HCC), and Cholangiocarcinoma.

Key Metrics

Founded Year

2019

Location

Basel, Switzerland

Stage

Series D

Total Funding

$366M in 4 rounds

Latest Funding Round

Series D, Nov 12, 2024, $*****

Post Money Valuation

$***** as on Jun 15, 2021

Investors

Novo Holdings & 16 more

Ranked

20^th among 249 active competitors

Employee Count

72 as on Jun 30, 2026

Similar Companies

argenx & 298 more

View Alentis Therapeutics' full profile

Alentis Therapeutics has raised a total funding of $366M over 4 rounds. Its first funding round was on Apr 29, 2019. Its latest funding round was a Series D round on Nov 12, 2024 for $*****. 8 investors participated in its latest round. Alentis Therapeutics has 17 institutional investors.

Here is the list of recent funding rounds of Alentis Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 12, 2024	4164871	Series D	2567794	3052625	1645932	5893082
Apr 13, 2023	9197063	Series C	6129410	7761131	5570444	Pureos Bioventures & 2 more
Jun 15, 2021	9121694	Series B	2941411	4175730	Morningside	Jeito & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of Alentis Therapeutics's funding rounds and investors

The founders of Alentis Therapeutics is Thomas Baumert.

Here are the details of Alentis Therapeutics' key team members:

Thomas Baumert: Founder & Board Member of Alentis Therapeutics.
Contact Info: 1 email address

View details of Alentis Therapeutics's Founder profiles and Board Members

Alentis Therapeutics' employee count trend

Alentis Therapeutics has 72 employees as of Jun 26. Here is Alentis Therapeutics's employee count trend over the years:

Employee count trend for Alentis Therapeutics

Uncover Alentis Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Alentis Therapeutics include argenx, Alexion and Halozyme. Here is the list of Top 10 competitors of Alentis Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 20 others	75/100
2nd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
3rd	Halozyme 1999, San Diego (United States), Public	Developer of drug delivery technologies for the treatment of various diseases	-	Colt Ventures, Third Security & 8 others	67/100
4th	Zai Lab 2013, Shanghai (China), Public	Developer of drugs for anti-cancer and anti-inflammatory diseases	$160M	HongShan, Kleiner Perkins & 9 others	67/100
5th	XOMA Corporation 1981, Berkeley (United States), Acquired	Developer of antibody-based therapeutics for treating endocrine/metabolic diseases	-	Ignite 500, Hercules Capital & 5 others	65/100
6th	Kodiak Sciences 2009, Palo Alto (United States), Public	Developer of therapeutics to treat retinal diseases	$35.8M	ArrowMark Partners, Perceptive Advisors & 1 others	63/100
7th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	63/100
8th	IgGenix 2019, San Francisco (United States), Series B	Developer of therapeutic solutions for treating food allergy	$75M	Khosla Ventures, Alexandria & 7 others	62/100
9th	Jasper Therapeutics 1999, Redwood City (United States), Series A	Developer of therapeutics for chronic diseases by targeting mast cells and stem cells	$50M	Abingworth, Qiming & 5 others	62/100
10th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	62/100
20th	Alentis Therapeutics 2019, Basel (Switzerland), Series D	Developer of therapies for treating fibrosis, cirrhosis, and liver cancer	$366M	Longitude Capital, Frazier Life Sciences ... & 15 others	58/100